Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	Semaglutide 1.0 mg	403
Overall Study	STARTED	Semaglutide 2.4 mg	404
Overall Study	STARTED	Placebo	403
Overall Study	Exposed	Semaglutide 1.0 mg	402
Overall Study	Exposed	Semaglutide 2.4 mg	403
Overall Study	Exposed	Placebo	402
Overall Study	Full Analysis Set (FAS)	Semaglutide 1.0 mg	403
Overall Study	Full Analysis Set (FAS)	Semaglutide 2.4 mg	404
Overall Study	Full Analysis Set (FAS)	Placebo	403
Overall Study	Safety Analysis Set (SAS)	Semaglutide 1.0 mg	402
Overall Study	Safety Analysis Set (SAS)	Semaglutide 2.4 mg	403
Overall Study	Safety Analysis Set (SAS)	Placebo	402
Overall Study	COMPLETED	Semaglutide 1.0 mg	390
Overall Study	COMPLETED	Semaglutide 2.4 mg	391
Overall Study	COMPLETED	Placebo	383
Overall Study	NOT COMPLETED	Semaglutide 1.0 mg	13
Overall Study	NOT COMPLETED	Semaglutide 2.4 mg	13
Overall Study	NOT COMPLETED	Placebo	20

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03552757/flow